SPECIAL NOTICE: DEVELOPMENT OF VACCINES FOR SEVERE ACUTE RESPIRATORY SYNDROME 
(SARS) – 266-02-SARSVAC

RELEASE DATE:  April 25, 2003

NOTICE: NOT-AI-03-025

National Institute of Allergy and Infectious Diseases (NIAID) 
 (http://www.niaid.nih.gov)

RECEIPT DATE: May 16, 2003

DESCRIPTION

The National Institute of Allergy and Infectious Diseases (NIAID), National 
Institutes of Health (NIH), DHHS is seeking capability statements from 
organizations with the expertise to develop vaccines for Severe Acute 
Respiratory Syndrome (SARS).  The purpose this effort is to identify 
commercial entities capable of the discovery, development and production of 
vaccines to prevent the disease caused by the newly recognized coronavirus 
that causes Severe Acute Respiratory Syndrome or SARS.  The respondent should 
consider the following elements:

1.  The U. S. government is mindful of the epidemiologic exigencies created 
by the emergence of this new virus and wishes to accelerate the development 
of appropriate interventions where possible. 
2.  The research and development needed to obtain a vaccine that will satisfy 
regulatory requirements of the FDA.
3.  The possible need to provide substantial supplies of this vaccine.  For 
purposes of this response the responder should consider the requirement for 
large-scale production of this material.
4.  The ability to conduct preclinical and clinical testing of the product.  
5.  Documented history of successful development of a vaccine for human use 
in the United States is essential.
6.  The U.S. government may also provide access to samples of the SARS virus. 
The research and development will require BSL-3 level facilities if work is 
proposed with the SARS virus in the laboratory.

NIAID is interested in receiving letters of interest and capability 
statements from interested organizations.  Interested organizations should 
submit their capability statements that contain descriptions of their 
potential development plans, their research and development capabilities and 
interests, summary results of pre-clinical and early clinical testing if 
available, and their potential or available manufacturing capabilities for 
large quantities of this vaccine.  Any perceived barriers to the conduct of 
this research should also be indicated.  The capability statements, along 
with any supporting documentations should not exceed 15 pages.  It is also 
requested that interested organizations indicate their overall cost estimate 
for their proposed effort.  The NIAID is not requesting a detailed cost 
proposal but rather an overall estimate of the effort per major line item.  
Capability statements and letters of interest will be kept confidential and 
will help in determining the need for an RFP to support research and 
development activities and in assembling a potential source list for 
distribution of any resultant RFP.  This is not a Request for Proposals and 
does not commit the Government to award a contract now or in the future.  
Submission of any information based on this request for information is purely 
voluntary.  Please specify, if applicable, the small business size status of 
your company (See Federal Acquisition Regulations, Part 19).  No solicitation 
is available at this time.  No collect calls will be accepted.  Submit your 
responses to Sharon Kraft, Contract Specialist, at the address listed in this 
special notice.

266-02-SARSVAC will be available electronically on or about April 22, 2003 
and may be accessed through the Internet on the Contract Management Branch 
Homepage, located at http://www.niaid.nih.gov/contract and will be posted on 
FedBizOpps at  http://www.eps.gov/servlet/Documents/R/634413. 
Responses to this Special Notice will be due on Friday, May 16, 2003.  

Contracting Office Address:

National Institutes of Health
National Institutes of Allergy and Infectious Diseases
Contract Management Branch 
6700-B Rockledge Drive
Room 2230, MSC 7612 
Bethesda, MD, 20892-7612

Point of Contact:

Sharon Kraft, Contract Specialist, Phone 301-402-5825, Fax 301-402-0972, 
Email sk371c@nih.gov

Return to Volume Index

Return to NIH Guide Main Index

	Office of Extramural Research (OER)			National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892			Department of Health and Human Services (HHS)
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, RealPlayer, Video or Flash files, see Help Downloading Files.